CA2753208C - Methods and compositions for the differentiation of stem cells - Google Patents
Methods and compositions for the differentiation of stem cells Download PDFInfo
- Publication number
- CA2753208C CA2753208C CA2753208A CA2753208A CA2753208C CA 2753208 C CA2753208 C CA 2753208C CA 2753208 A CA2753208 A CA 2753208A CA 2753208 A CA2753208 A CA 2753208A CA 2753208 C CA2753208 C CA 2753208C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- medium
- differentiation
- cell
- pluripotent stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004069 differentiation Effects 0.000 title claims abstract description 196
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 160
- 238000000034 method Methods 0.000 title claims abstract description 144
- 239000000203 mixture Substances 0.000 title abstract description 25
- 210000004027 cell Anatomy 0.000 claims abstract description 231
- 239000002609 medium Substances 0.000 claims abstract description 226
- 210000001778 pluripotent stem cell Anatomy 0.000 claims abstract description 94
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 38
- 210000002966 serum Anatomy 0.000 claims abstract description 35
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 34
- 239000011159 matrix material Substances 0.000 claims abstract description 33
- 230000001146 hypoxic effect Effects 0.000 claims abstract description 31
- 239000003102 growth factor Substances 0.000 claims abstract description 25
- 210000003593 megakaryocyte Anatomy 0.000 claims abstract description 19
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 15
- 210000003714 granulocyte Anatomy 0.000 claims abstract description 12
- 210000002540 macrophage Anatomy 0.000 claims abstract description 10
- 238000012258 culturing Methods 0.000 claims description 56
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 47
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 47
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 41
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 38
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 35
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 35
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 35
- 239000001963 growth medium Substances 0.000 claims description 29
- 239000003112 inhibitor Substances 0.000 claims description 29
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 28
- 108010035532 Collagen Proteins 0.000 claims description 28
- 102000008186 Collagen Human genes 0.000 claims description 28
- 229920001436 collagen Polymers 0.000 claims description 28
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 28
- 108010067306 Fibronectins Proteins 0.000 claims description 26
- 102000000646 Interleukin-3 Human genes 0.000 claims description 26
- 108010002386 Interleukin-3 Proteins 0.000 claims description 26
- 102000004889 Interleukin-6 Human genes 0.000 claims description 26
- 108090001005 Interleukin-6 Proteins 0.000 claims description 26
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 26
- 239000012298 atmosphere Substances 0.000 claims description 26
- 229940076264 interleukin-3 Drugs 0.000 claims description 26
- 229940100601 interleukin-6 Drugs 0.000 claims description 26
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 22
- 239000001301 oxygen Substances 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims description 21
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims description 21
- 102000000568 rho-Associated Kinases Human genes 0.000 claims description 21
- 108010041788 rho-Associated Kinases Proteins 0.000 claims description 21
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 20
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims description 20
- 102100039564 Leukosialin Human genes 0.000 claims description 20
- 229960002897 heparin Drugs 0.000 claims description 20
- 229920000669 heparin Polymers 0.000 claims description 20
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 19
- 229930182816 L-glutamine Natural products 0.000 claims description 19
- 230000004083 survival effect Effects 0.000 claims description 19
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 18
- 229910001882 dioxygen Inorganic materials 0.000 claims description 18
- 239000003797 essential amino acid Substances 0.000 claims description 18
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 18
- 235000020776 essential amino acid Nutrition 0.000 claims description 17
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 16
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 13
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 10
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000010899 nucleation Methods 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 229960005322 streptomycin Drugs 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 102000005640 Myosin Type II Human genes 0.000 claims description 8
- 108010045128 Myosin Type II Proteins 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 8
- 239000011707 mineral Substances 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 6
- 210000004443 dendritic cell Anatomy 0.000 claims description 6
- 210000003630 histaminocyte Anatomy 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- 229940024606 amino acid Drugs 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 108700014844 flt3 ligand Proteins 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 claims description 3
- 230000001361 thrombopoietic effect Effects 0.000 claims 5
- 102000003505 Myosin Human genes 0.000 claims 2
- 108060008487 Myosin Proteins 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract description 73
- 230000003511 endothelial effect Effects 0.000 abstract description 37
- 239000000126 substance Substances 0.000 abstract description 15
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 239000006143 cell culture medium Substances 0.000 abstract description 5
- 238000007423 screening assay Methods 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 description 42
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 35
- 102100037362 Fibronectin Human genes 0.000 description 25
- 102000036693 Thrombopoietin Human genes 0.000 description 24
- 108010041111 Thrombopoietin Proteins 0.000 description 24
- -1 SCF Proteins 0.000 description 14
- 230000003394 haemopoietic effect Effects 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 210000002242 embryoid body Anatomy 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 229920000609 methyl cellulose Polymers 0.000 description 8
- 239000001923 methylcellulose Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000000925 erythroid effect Effects 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 102100037241 Endoglin Human genes 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 108010054218 Factor VIII Proteins 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108010022164 acetyl-LDL Proteins 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 235000021120 animal protein Nutrition 0.000 description 3
- LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960000301 factor viii Drugs 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001436672 Bhatia Species 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010036395 Endoglin Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 102000028180 Glycophorins Human genes 0.000 description 2
- 108091005250 Glycophorins Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 210000003566 hemangioblast Anatomy 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 102000044493 human CDCA4 Human genes 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 108010071003 insulin-related factor Proteins 0.000 description 2
- 229940074383 interleukin-11 Drugs 0.000 description 2
- 229940118526 interleukin-9 Drugs 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- WEEFNMFMNMASJY-UHFFFAOYSA-M 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 WEEFNMFMNMASJY-UHFFFAOYSA-M 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NEBCAMAQXZIVRE-UHFFFAOYSA-N 5-(methoxymethyl)-4-[2,3,4-trihydroxy-6-(methoxymethyl)phenyl]benzene-1,2,3-triol Chemical compound COCC1=CC(O)=C(O)C(O)=C1C1=C(O)C(O)=C(O)C=C1COC NEBCAMAQXZIVRE-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 101100394749 Arabidopsis thaliana HSFB2A gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100454433 Biomphalaria glabrata BG01 gene Proteins 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 101000766308 Bos taurus Serotransferrin Proteins 0.000 description 1
- IYOZTVGMEWJPKR-YWRZDDHQSA-N C1C[C@@H](C(N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 Chemical compound C1C[C@@H](C(N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-YWRZDDHQSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- VDRZDTXJMRRVMF-UONOGXRCSA-N D-erythro-sphingosine Natural products CCCCCCCCCC=C[C@@H](O)[C@@H](N)CO VDRZDTXJMRRVMF-UONOGXRCSA-N 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 description 1
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100032606 Heat shock factor protein 1 Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101150094793 Hes3 gene Proteins 0.000 description 1
- 101150029234 Hes5 gene Proteins 0.000 description 1
- 101000878124 Homo sapiens Fibroblast growth factor 17 Proteins 0.000 description 1
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 description 1
- 101000867525 Homo sapiens Heat shock factor protein 1 Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 229910013470 LiC1 Inorganic materials 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100019404 Mus musculus Itgb1 gene Proteins 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- FNPHNLNTJNMAEE-HSZRJFAPSA-N O-octadecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FNPHNLNTJNMAEE-HSZRJFAPSA-N 0.000 description 1
- XOMRRQXKHMYMOC-UHFFFAOYSA-N O-palmitoylcarnitine Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-UHFFFAOYSA-N 0.000 description 1
- 208000014245 Ocular vascular disease Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101100070550 Oryza sativa subsp. japonica HSFA2C gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010084535 ProNectin F Proteins 0.000 description 1
- 101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- OBZJZDHRXBKKTJ-UHFFFAOYSA-N Sangivamycin Natural products C12=NC=NC(N)=C2C(C(=O)N)=CN1C1OC(CO)C(O)C1O OBZJZDHRXBKKTJ-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- JKNIRLKHOOMGOJ-UHFFFAOYSA-N cladochrome D Natural products COC1=C(CC(C)OC(=O)Oc2ccc(O)cc2)c3c4C(=C(OC)C(=O)c5c(O)cc(OC)c(c45)c6c(OC)cc(O)c(C1=O)c36)CC(C)OC(=O)c7ccc(O)cc7 JKNIRLKHOOMGOJ-UHFFFAOYSA-N 0.000 description 1
- SRJYZPCBWDVSGO-UHFFFAOYSA-N cladochrome E Natural products COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1 SRJYZPCBWDVSGO-UHFFFAOYSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960001378 dequalinium chloride Drugs 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 230000006517 limb development Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229950008902 safingol Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- OBZJZDHRXBKKTJ-JTFADIMSSA-N sangivamycin Chemical compound C12=NC=NC(N)=C2C(C(=O)N)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OBZJZDHRXBKKTJ-JTFADIMSSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000004897 thiazines Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15421009P | 2009-02-20 | 2009-02-20 | |
| US61/154,210 | 2009-02-20 | ||
| PCT/US2010/024881 WO2010096746A1 (en) | 2009-02-20 | 2010-02-22 | Methods and compositions for the differentiation of stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2753208A1 CA2753208A1 (en) | 2010-08-26 |
| CA2753208C true CA2753208C (en) | 2018-08-21 |
Family
ID=42101531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2753208A Active CA2753208C (en) | 2009-02-20 | 2010-02-22 | Methods and compositions for the differentiation of stem cells |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8557580B2 (enExample) |
| EP (1) | EP2398897B1 (enExample) |
| JP (3) | JP6189581B2 (enExample) |
| CA (1) | CA2753208C (enExample) |
| WO (1) | WO2010096746A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0817751A2 (pt) | 2007-09-28 | 2017-06-13 | Anthrogenesis Corp | método para suprimir a proliferação de células de tumor, e, composição |
| CN102395672A (zh) * | 2009-04-13 | 2012-03-28 | 加利福尼亚大学董事会 | 用于干细胞培养的方法和组合物 |
| US9428735B2 (en) | 2010-02-25 | 2016-08-30 | The Johns Hopkins University | Smooth muscle-like cells (SMLCs) dervided from human pluripotent stem cells |
| AU2011250651B2 (en) * | 2010-05-05 | 2015-10-08 | Genea Ip Holdings Pty Limited | Media and methods for cell culture |
| US20120064040A1 (en) * | 2010-06-03 | 2012-03-15 | The Regents Of The University Of California | Serum free culture medium and supplement |
| US8926964B2 (en) * | 2010-07-13 | 2015-01-06 | Anthrogenesis Corporation | Methods of generating natural killer cells |
| WO2012018933A2 (en) | 2010-08-04 | 2012-02-09 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
| CN106119200A (zh) * | 2010-09-10 | 2016-11-16 | 国立大学法人东京大学 | 涉及由多能干细胞向血细胞分化的培养方法 |
| US20130295669A1 (en) | 2010-11-09 | 2013-11-07 | Lonza Cologne Gmbh | Method for controlling binding of cells to a substrate |
| JP6163104B2 (ja) | 2010-11-15 | 2017-07-12 | アクセラレイテッド・バイオサイエンシズ・コーポレーション | ヒト・トロホブラスト幹細胞からの神経幹細胞の生成 |
| US20140045265A1 (en) * | 2011-02-16 | 2014-02-13 | Salk Institute For Biological Studies | Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors |
| JP5995247B2 (ja) * | 2011-02-23 | 2016-09-21 | 国立大学法人京都大学 | 多能性幹細胞から樹状細胞を製造する方法 |
| EP2697360A1 (en) * | 2011-04-11 | 2014-02-19 | Jaffar Ali Bin M. Abdullah | Protein-free culture media products |
| PL2761065T3 (pl) * | 2011-09-29 | 2018-02-28 | Cellsnap, Llc | Kompozycje i sposoby do testów toksykogenności |
| US10428309B2 (en) | 2011-12-01 | 2019-10-01 | New York Stem Cell Foundation, Inc. | Systems and methods for producing stem cells and differentiated cells |
| KR102631374B1 (ko) * | 2011-12-01 | 2024-01-29 | 뉴욕 스템 셀 파운데이션, 인코포레이티드 | 유도 다능성 줄기 세포 또는 분화된 세포를 제조하기 위한 자동화 시스템 |
| EP2788475A1 (en) | 2011-12-05 | 2014-10-15 | Primorigen Biosciences Inc. | Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof |
| CA2865497A1 (en) * | 2012-02-29 | 2013-09-06 | The Johns Hopkins University | Method for guiding the derivation of endothelial cells from human pluripotent stem cells employing two-dimensional, feeder-free differentiation |
| AU2013349725B2 (en) | 2012-11-21 | 2016-05-12 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for determination of botulinum neurotoxin biological activity |
| EP2925860B8 (en) | 2012-11-30 | 2019-12-25 | Accelerated BioSciences Corp. | Methods of differentiating stem cells by modulating mir-124 |
| CN105101979B (zh) * | 2012-12-21 | 2021-10-08 | 安斯泰来再生医药协会 | 由多能干细胞制备血小板的方法及其组合物 |
| CN105142651A (zh) | 2013-02-05 | 2015-12-09 | 人类起源公司 | 来自胎盘的自然杀伤细胞 |
| US9506037B2 (en) | 2013-03-15 | 2016-11-29 | The Johns Hopkins University | Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix |
| EP2777703B1 (en) * | 2013-03-15 | 2016-09-14 | Lonza Cologne GmbH | Compositions and methods for enhancing the therapeutic potential of stem cells |
| US9994825B2 (en) | 2013-03-15 | 2018-06-12 | The Johns Hopkins University | Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix |
| JP6608357B2 (ja) | 2013-06-28 | 2019-11-20 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法 |
| WO2015097920A1 (ja) * | 2013-12-27 | 2015-07-02 | 京都府公立大学法人 | 角膜内皮細胞の細胞治療併用剤 |
| WO2015119642A1 (en) * | 2014-02-10 | 2015-08-13 | The Johns Hopkins University | Low oxygen tension enhances endothelial fate of human pluripotent stem cells |
| CA2940082C (en) | 2014-02-19 | 2023-09-19 | Merz Pharma Gmbh & Co. Kgaa | Gangliosides for standardizing and increasing the sensitivity of cells to botulinum neurotoxins in in vitro test systems |
| AU2015249371B2 (en) | 2014-04-24 | 2020-04-30 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| WO2016086132A1 (en) | 2014-11-26 | 2016-06-02 | Accelerated Biosciences Corp. | Induced hepatocytes and uses thereof |
| CA2971271C (en) | 2014-12-19 | 2022-09-06 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the biological activity of bont/e in cells |
| JP6800859B2 (ja) | 2015-01-26 | 2020-12-16 | フェイト セラピューティクス，インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
| TWI704156B (zh) | 2015-03-04 | 2020-09-11 | 德商曼茲法瑪股份有限公司 | 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法 |
| JP7534070B2 (ja) | 2015-11-04 | 2024-08-14 | フェイト セラピューティクス，インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
| CN108368520B (zh) | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| CN111334463B (zh) * | 2016-05-18 | 2024-02-20 | 学校法人庆应义塾 | 类器官培养用细胞培养基、培养方法及类器官 |
| CA3087344A1 (en) | 2018-01-05 | 2019-07-11 | Platelet Biogenesis, Inc. | Compositions and methods for producing megakaryocytes |
| EP3813853A4 (en) | 2018-06-29 | 2022-04-06 | Platelet Biogenesis, Inc. | DELIVERY COMPOSITIONS AND METHODS OF USE |
| US12497593B2 (en) | 2018-09-07 | 2025-12-16 | Wisconsin Alumni Research Foundation | Generation of hematopoietic progenitor cells from human pluripotent stem cells |
| CN110438065B (zh) * | 2019-07-25 | 2020-06-05 | 中山大学 | 一种诱导人诱导性多能干细胞分化为内皮祖细胞的方法 |
| US20220411755A1 (en) * | 2019-11-14 | 2022-12-29 | Amgen Inc. | Hematopoietic precursor cell production |
| CN115956117A (zh) * | 2020-08-21 | 2023-04-11 | Jsr株式会社 | 人类人工多能干细胞的培养方法、人类人工多能干细胞培养物、以及脑类器官的制造方法 |
| WO2024018018A1 (fr) | 2022-07-21 | 2024-01-25 | Etablissement Francais Du Sang | Utilisation d'un composé vitisine pour la production de cellules hématopoïétiques |
| WO2025126208A1 (en) * | 2023-12-12 | 2025-06-19 | Accellta Ltd. | Media for maintaining, differentiating, or both, pluripotent stem cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0018737B1 (en) | 1979-04-11 | 1983-11-09 | Mitsui Petrochemical Industries, Ltd. | Process for producing spherical carrier particles for olefin polymerisation catalyst, catalyst comprising such carrier particles, and use of such catalyst in olefin polymerisation |
| GB9807935D0 (en) * | 1998-04-14 | 1998-06-10 | Univ Edinburgh | Lineage specific cells and progenitor cells |
| CA2277278A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
| CN1187090C (zh) | 1999-03-25 | 2005-02-02 | 三菱制药株式会社 | 间质性肺炎、肺纤维化症的预防和治疗药 |
| AU5250400A (en) | 1999-06-18 | 2001-01-09 | Mitsubishi Pharma Corporation | Osteogenesis promoters |
| JP4563573B2 (ja) * | 2000-12-07 | 2010-10-13 | 株式会社カネカ | 抗原およびこの抗原を識別するモノクローナル抗体 |
| ES2298497T3 (es) | 2002-01-23 | 2008-05-16 | Bayer Pharmaceuticals Corporation | Inhibidores de quinasa rho. |
| US6664266B2 (en) | 2002-03-14 | 2003-12-16 | Children's Medical Center Corporation | Axon regeneration with PKC inhibitiors |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| CA2482598C (en) | 2002-04-22 | 2012-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase c |
| US7427603B2 (en) | 2002-09-26 | 2008-09-23 | The Children's Medical Center Corporation | Method of enhancing proliferation and/or hematopoietic differentiation of stem cells |
| CA2579643C (en) | 2004-09-08 | 2011-12-06 | Wisconsin Alumni Research Foundation | Medium and culture of embryonic stem cells |
| EP3196296B1 (en) | 2004-09-08 | 2018-11-21 | Wisconsin Alumni Research Foundation | Culturing human embryonic stem cells |
| AU2005302258B2 (en) | 2004-11-01 | 2010-10-21 | Wisconsin Alumni Research Foundation | Platelets from stem cells |
| US7732445B2 (en) | 2006-07-21 | 2010-06-08 | Northwestern University | Myosin light chain kinase inhibitor compounds, compostions and related methods of use |
| JP2008099662A (ja) * | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
| GB2458863B (en) * | 2007-01-17 | 2011-10-12 | Wisconsin Alumni Res Found | Improved culture of stem cells |
| CN101743306A (zh) | 2007-03-23 | 2010-06-16 | 威斯康星校友研究基金会 | 体细胞重编程 |
| JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| DK3293256T3 (da) | 2007-06-29 | 2019-08-12 | Fujifilm Cellular Dynamics Inc | Automatiseret fremgangsmåde og apparatur til dyrkning af embryonale stamceller |
| WO2009135206A1 (en) | 2008-05-02 | 2009-11-05 | Stem Cell Products, Inc. | Method for production of mast cells from stem cells |
-
2010
- 2010-02-22 JP JP2011551266A patent/JP6189581B2/ja active Active
- 2010-02-22 US US12/709,764 patent/US8557580B2/en active Active
- 2010-02-22 WO PCT/US2010/024881 patent/WO2010096746A1/en not_active Ceased
- 2010-02-22 CA CA2753208A patent/CA2753208C/en active Active
- 2010-02-22 EP EP10705729.1A patent/EP2398897B1/en active Active
-
2015
- 2015-10-30 JP JP2015213836A patent/JP2016019543A/ja active Pending
-
2017
- 2017-06-08 JP JP2017113273A patent/JP6691509B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2398897B1 (en) | 2017-06-28 |
| US20100216181A1 (en) | 2010-08-26 |
| US8557580B2 (en) | 2013-10-15 |
| EP2398897A1 (en) | 2011-12-28 |
| WO2010096746A1 (en) | 2010-08-26 |
| JP2017148079A (ja) | 2017-08-31 |
| JP2012518415A (ja) | 2012-08-16 |
| JP2016019543A (ja) | 2016-02-04 |
| JP6189581B2 (ja) | 2017-08-30 |
| JP6691509B2 (ja) | 2020-04-28 |
| CA2753208A1 (en) | 2010-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2753208C (en) | Methods and compositions for the differentiation of stem cells | |
| JP5816100B2 (ja) | 多能性細胞の分化 | |
| JP2012519005A5 (enExample) | ||
| CA2905786C (en) | Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions | |
| JP6339998B2 (ja) | 幹細胞よりナチュラルキラー細胞を発生させる方法 | |
| JP5632831B2 (ja) | 幹細胞からの肥満細胞の生産のための方法 | |
| CN102206610B (zh) | 造血祖细胞的制备方法及其专用培养基 | |
| WO2025201290A1 (zh) | 一种制备血小板的方法 | |
| HK1218927B (en) | Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141229 |